Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Sloand EM, Melenhorst JJ, Tucker ZC, Pfannes L, Brenchley JM, Yong A, Visconte V, Wu C, Gostick E, Scheinberg P, Olnes MJ, Douek DC, Price DA, Barrett AJ, Young NS.

Blood. 2011 Mar 3;117(9):2691-9. doi: 10.1182/blood-2010-04-277921.

2.

Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, Lu J, Basu A, Barrett AJ, Young NS.

Blood. 2005 Aug 1;106(3):841-51.

3.

T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.

Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, Barrett AJ.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807.

4.

Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.

Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H.

Cancer Sci. 2010 Mar;101(3):594-600. doi: 10.1111/j.1349-7006.2009.01453.x.

5.

Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.

Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, Hilgendorf I, Hirt C, Ho AD, Freund M, Schmitt M.

Int J Cancer. 2016 Apr 1;138(7):1792-801. doi: 10.1002/ijc.29909.

PMID:
26519872
6.

[Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].

Gu WY, Chen ZX, Qiu GQ, Hu SY, Jia L, Wu W, He J, Cen JN, He B.

Zhonghua Yi Xue Za Zhi. 2008 Dec 30;88(48):3401-6. Chinese.

PMID:
19159569
7.

Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow.

Van Dijk JP, Knops GH, Van De Locht LT, Menke AL, Jansen JH, Mensink EJ, Raymakers RA, De Witte T.

Br J Haematol. 2002 Sep;118(4):1027-33.

PMID:
12199781
8.

Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. Erratum in: Clin Cancer Res. 2007 Sep 1;13(17):5226.

9.

Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.

Falkenburg WJ, Melenhorst JJ, van de Meent M, Kester MG, Hombrink P, Heemskerk MH, Hagedoorn RS, Gostick E, Price DA, Falkenburg JH, Barrett AJ, Jedema I.

J Immunol. 2011 Sep 1;187(5):2824-33. doi: 10.4049/jimmunol.1100852.

10.

Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.

Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ.

Blood. 2007 Sep 15;110(6):1924-32.

11.

Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.

Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Inoue H, Yasukawa M.

PLoS One. 2013;8(2):e56820. doi: 10.1371/journal.pone.0056820.

12.

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Blood. 2011 Aug 11;118(6):1495-503. doi: 10.1182/blood-2011-02-337089.

13.

Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.

Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H.

Microbiol Immunol. 2008 Nov;52(11):551-8. doi: 10.1111/j.1348-0421.2008.00069.x.

14.

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ.

Blood. 2008 Jan 1;111(1):236-42.

15.

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U.

Blood. 2002 Sep 15;100(6):2132-7.

16.
17.

[Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].

Lu D, Qin YZ, Li LD, Shi HX, Lai YY, Liu YR.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):370-6. doi: 10.7534/j.issn.1009-2137.2014.02.019. Chinese.

PMID:
24763007
18.

Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.

Wu F, Oka Y, Tsuboi A, Elisseeva OA, Ogata K, Nakajima H, Fujiki F, Masuda T, Murakami M, Yoshihara S, Ikegame K, Hosen N, Kawakami M, Nakagawa M, Kubota T, Soma T, Yamagami T, Tsukaguchi M, Ogawa H, Oji Y, Hamaoka T, Kawase I, Sugiyama H.

Leukemia. 2005 Feb;19(2):268-74.

PMID:
15538407
19.

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.

Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK.

Blood. 2008 Oct 1;112(7):2956-64. doi: 10.1182/blood-2008-02-137695.

20.

In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.

Zheng Z, Qianqiao Z, Qi H, Feng X, Chunkang C, Xiao L.

Exp Hematol. 2010 Aug;38(8):677-84. doi: 10.1016/j.exphem.2010.04.002.

PMID:
20394797
Items per page

Supplemental Content

Support Center